LA JOLLA, Calif.
July 23, 2013
Regulus Therapeutics Inc.
(NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting
RNAs, announced today the completion of an underwritten public offering of 5,175,000 shares of common stock, including 675,000 shares sold pursuant to the full exercise of an option to purchase additional shares previously granted to the underwriters, at a price to the public of
per share. The gross proceeds to Regulus from this offering were approximately
, before deducting underwriting discounts and commissions and estimated offering expenses payable by Regulus.
Lazard Capital Markets LLC, Cowen and Company, LLC and BMO Capital Markets Corp acted as joint book-running managers for the offering. Needham & Company, LLC and Wedbush PacGrow Life Sciences acted as co-managers.
The securities described above were offered by Regulus pursuant to a registration statement filed with the Securities and Exchange Commission ("SEC"), which the SEC declared effective on
July 16, 2013
The offering was made by means of a prospectus, copies of which may be obtained from Lazard Capital Markets LLC, Attn: Syndicate Department, 30 Rockefeller Plaza, 48th Floor,
New York, NY
10112, Telephone: (800) 542-0970; from Cowen and Company, LLC (c/o Broadridge Financial Services, 1155 Long Island Avenue,
11717, Attn: Prospectus Department, Telephone: (631) 274-2806, Fax: 631-254-7140); or from BMO Capital Markets Corp, Attention: Equity Syndicate Department, 3 Times Square
New York, NY
10036, Telephone: (800) 414-3627, E-mail:
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.